Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Bioverativ Inc (NASDAQ:BIVV) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,410 shares of the biotechnology company’s stock, valued at approximately $252,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new stake in shares of Bioverativ during the 3rd quarter worth $137,000. TCI Wealth Advisors Inc. purchased a new stake in shares of Bioverativ during the 3rd quarter worth $186,000. Canada Pension Plan Investment Board purchased a new stake in shares of Bioverativ during the 3rd quarter worth $194,000. ACG Wealth purchased a new stake in shares of Bioverativ during the 3rd quarter worth $205,000. Finally, Roberts Glore & Co. Inc. IL purchased a new stake in shares of Bioverativ during the 3rd quarter worth $232,000. 95.23% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages recently weighed in on BIVV. Deutsche Bank set a $53.00 price objective on Bioverativ and gave the stock a “hold” rating in a research note on Monday, November 20th. Zacks Investment Research cut Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Piper Jaffray Companies reiterated an “overweight” rating and issued a $71.00 price target on shares of Bioverativ in a research note on Monday, October 23rd. Morgan Stanley reiterated an “underweight” rating and issued a $47.00 price target (up from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Finally, Argus upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research note on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $60.93.
Shares of Bioverativ Inc (NASDAQ BIVV) opened at $50.25 on Wednesday. Bioverativ Inc has a 12 month low of $40.00 and a 12 month high of $64.41.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.25. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The firm had revenue of $291.60 million during the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ’s revenue was up 27.2% on a year-over-year basis. equities research analysts expect that Bioverativ Inc will post 2.45 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “4,410 Shares in Bioverativ Inc (BIVV) Purchased by Zurcher Kantonalbank Zurich Cantonalbank” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://ledgergazette.com/2017/12/06/4410-shares-in-bioverativ-inc-bivv-purchased-by-zurcher-kantonalbank-zurich-cantonalbank.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.